AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Strensiq (asfotase alfa) by Year
Strensiq (asfotase alfa) — Established RoW YoY actual (%) (%)
AstraZeneca Strensiq (asfotase alfa): 23.0% in FY2025, up 11.0 pts from a year earlier.
Latest, FY2025
23.0%
Period ended Dec 31, 2025
Change on a year earlier
+11.0 pts
12.0% in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Strensiq | 1,678 | 19 | 18 | 1,332 | 14 | 104 | 94 | 84 | 123 | 25 | 21 | 119 | 23 | 23”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Strensiq (asfotase alfa) — Established RoW YoY actual (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 23.0% | +11.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 12.0% | -1.0 pts | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 13.0% | +14.0 pts | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | -1.0% | -10.0 pts | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 9.0% | – | Form 6-K FY2021Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Strensiq (asfotase alfa) (%), annual FY2021–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-strensiq-erow-act-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.